Repligen Corporation (RGEN)

Market Cap	6.64B
Revenue (ttm)	673.96M
Net Income (ttm)	-13.83M
Shares Out	56.26M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	61.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,720
Open	120.04
Previous Close	120.70
Day's Range	117.18 - 120.18
52-Week Range	102.97 - 182.52
Beta	1.07
Analysts	Buy
Price Target	167.38 (+41.9%)
Earnings Date	Jul 29, 2025

About RGEN

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,778
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN
• Website: https://www.repligen.com

Analyst Summary

According to 9 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $167.38, which is an increase of 41.90% from the latest price.

Price Target

$167.38

(41.90% upside)

Analyst Consensus: Buy